Masitinib Inhibits Hepatitis A Virus Replication
Abstract
:1. Introduction
2. Results
2.1. Construction of the HuhT7-HAV/Luc Cells Stably Expressing Hepatitis A Virus (HAV) HM175-18f Genotype IB Subgenomic Replicon Harboring the Firefly Luciferase Gene
2.2. Screening for 1134 Drugs Derived from FDA-Approved Drug Library for Anti-Hepatitis A Virus (HAV) Drugs in HuhT7-HAV/Luc Cells
2.3. Masitinib Significantly Inhibits Hepatitis A Virus (HAV) HA11-1299 Genotype IIIA Replication
2.4. Masitinib Significantly Inhibits Hepatitis A Virus (HAV) HM175-18f Genotype IB Replication
2.5. Masitinib Significantly Inhibits Hepatitis A Virus (HAV) HA11-1299 Genotype IIIA Replication in a Dose-Dependent Manner
2.6. Masitinib Significantly Inhibits the Activity of the Hepatitis A Virus (HAV) HM175 Genotype IB Internal Ribosomal Entry Site (IRES)-Mediated Translation in a Dose-Dependent Manner
3. Discussion
4. Materials and Methods
4.1. Cells and Reagents
4.2. Establishment of HuhT7-HAV/Luc Cells Stably Expressing HAV Subgenomic Replicon RNA Harboring the Firefly Luciferase Gene
4.3. Drug Screening in HuhT7-HAV/Luc Cells Stably Expressing HAV HM175 Genotype IB Subgenomic Replicon RNA Harboring the Firefly Luciferase Gene
4.4. Luciferase Reporter Assays
4.5. Cell Viability Assays
4.6. Examination of Anti-HAV Activities of Selected Drugs in HAV HA11-1299 Genotype IIIA-Infected Huh7 Cells
4.7. RNA Extraction and Quantification of HAV RNA and Actin mRNA
4.8. Calculation of the Half Maximal Inhibitory Concentration (IC50)
4.9. Immunofluorescence Staining
4.10. Statistical Analysis
5. Conclusions
6. Patents
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Jacobsen, K.H.; Wiersma, S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010, 28, 6653–6657. [Google Scholar] [CrossRef] [PubMed]
- Mendizabal, M.; Dip, M.; Demirdjian, E.; Lauferman, L.; Lopez, S.; Minetto, J.; Costaguta, A.; Rumbo, C.; Malla, I.; Sanchez, M.C.; et al. Changing Etiologies and Prognostic Factors in Pediatric Acute Liver Failure. Liver Transpl. 2020, 26, 268–275. [Google Scholar] [CrossRef] [PubMed]
- Bernal, W.; Auzinger, G.; Dhawan, A.; Wendon, J. Acute liver failure. Lancet 2010, 376, 190–201. [Google Scholar] [CrossRef] [PubMed]
- Lee, W.M.; Squires, R.H.; Nyberg, S.L.; Doo, E.; Hoofnagle, J.H. Acute liver failure: Summary of a workshop. Hepatology 2008, 47, 1401–1415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakao, M.; Nakayama, N.; Uchida, Y.; Tomiya, T.; Oketani, M.; Ido, A.; Tsubouchi, H.; Takikawa, H.; Mochida, S. Deteriorated outcome of recent patients with acute liver failure and late-onset hepatic failure caused by infection with hepatitis A virus: A subanalysis of patients seen between 1998 and 2015 and enrolled in nationwide surveys in Japan. Hepatol. Res. 2019, 8, 844–852. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.D.; Cho, E.J.; Ahn, C.; Park, S.K.; Choi, J.Y.; Lee, H.C.; Kim, D.Y.; Choi, M.S.; Wang, H.J.; Kim, I.H.; et al. A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. Hepatology 2019, 2, 621–629. [Google Scholar] [CrossRef] [PubMed]
- Aggarwal, R.; Goel, A. Hepatitis A: Epidemiology in resource-poor countries. Curr. Opin. Infect. Dis. 2015, 28, 488–496. [Google Scholar] [CrossRef] [PubMed]
- Cary, L.C.; Goebel, M.; Corsaro, B.G.; Wang, H.G.; Rosen, E.; Fraser, M.J. Transposon mutagenesis of baculoviruses: Analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. Virology 1989, 172, 156–169. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, S.; Ishihara, M.; Watanabe, S.; Ando, N.; Ohtsuka, M.; Sato, M. Intravenous Delivery of piggy Bac Transposons as a Useful Tool for Liver-Specific Gene-Switching. Int. J. Mol. Sci. 2018, 19, 3452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, S.; Wu, X.; Li, G.; Han, M.; Zhuang, Y.; Xu, T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 2005, 122, 473–483. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Esser-Nobis, K.; Harak, C.; Schult, P.; Kusov, Y.; Lohmann, V. Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication. Hepatology 2015, 2, 397–408. [Google Scholar] [CrossRef] [PubMed]
- National Library of Medicine: PubChem. Compound Summary: Masitinib. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Masitinib (accessed on 17 October 2022).
- Dubreuil, P.; Letard, S.; Ciufolini, M.; Gros, L.; Humbert, M.; Castéran, N.; Borge, L.; Hajem, B.; Lermet, A.; Sippl, W.; et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE 2009, 4, e7258. [Google Scholar] [CrossRef] [PubMed]
- Gauss-Müller, V.; Kusov, Y.Y. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J. Gen. Virol. 2002, 83, 2183–2192. [Google Scholar] [CrossRef] [PubMed]
- Kanda, T.; Sasaki, R.; Nakamoto, S.; Haga, Y.; Nakamura, M.; Shirasawa, H.; Okamoto, H.; Yokosuka, O. The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity. Biochem. Biophys. Res. Commun. 2015, 466, 567–571. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Kiyohara, T.; Kanda, T.; Imazeki, F.; Fujiwara, K.; Gauss-Müller, V.; Ishii, K.; Wakita, T.; Yokosuka, O. Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. Virol. J. 2010, 7, 212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sasaki-Tanaka, R.; Shibata, T.; Moriyama, M.; Okamoto, H.; Kogure, H.; Kanda, T. Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy. J. Virol. 2022, 96, e0064622. [Google Scholar] [CrossRef] [PubMed]
- Chuma, M.; Terashita, K.; Sakamoto, N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatol. Res. 2015, 45, E1–E11. [Google Scholar] [CrossRef] [PubMed]
- Lohmann, V.; Körner, F.; Koch, J.O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Casas, N.; Amarita, F.; de Marañón, I.M. Evaluation of an extracting method for the detection of Hepatitis A virus in shellfish by SYBR-Green real-time RT-PCR. Int. J. Food. Microbiol. 2007, 120, 179–185. [Google Scholar] [CrossRef] [PubMed]
- Sasaki-Tanaka, R.; Masuzaki, R.; Okamoto, H.; Shibata, T.; Moriyama, M.; Kogure, H.; Kanda, T. Drug Screening for Hepatitis A Virus (HAV): Nicotinamide Inhibits c-Jun Expression and HAV Replication. J. Virol. 2023, 97, e0198722. [Google Scholar] [CrossRef] [PubMed]
- Sasaki-Tanaka, R.; Shibata, T.; Okamoto, H.; Moriyama, M.; Kanda, T. Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. Int. J. Mol. Sci. 2022, 23, 2631. [Google Scholar] [CrossRef] [PubMed]
- Jiang, X.; Kanda, T.; Nakamoto, S.; Saito, K.; Nakamura, M.; Wu, S.; Haga, Y.; Sasaki, R.; Sakamoto, N.; Shirasawa, H.; et al. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells. Biochem. Biophys. Res. Commun. 2015, 458, 908–912. [Google Scholar] [CrossRef] [PubMed]
- Kanda, T.; Yokosuka, O.; Imazeki, F.; Fujiwara, K.; Nagao, K.; Saisho, H. Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem. Biophys. Res. Commun. 2005, 331, 621–629. [Google Scholar] [CrossRef] [PubMed]
- Miyamura, T.; Ishii, K.; Kanda, T.; Tawada, A.; Sekimoto, T.; Wu, S.; Nakamoto, S.; Arai, M.; Fujiwara, K.; Imazeki, F.; et al. Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure. Hepatol. Res. 2012, 3, 248–253. [Google Scholar] [CrossRef] [PubMed]
- Bruni, R.; Taffon, S.; Equestre, M.; Cella, E.; Lo Presti, A.; Costantino, A.; Chionne, P.; Madonna, E.; Golkocheva-Markova, E.; Bankova, D.; et al. Hepatitis a virus genotypes and strains from an endemic area of Europe, Bulgaria 2012–2014. BMC Infect. Dis. 2017, 17, 497. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ameen, A.; Sabeena, S.; Robin, S.; Sanjay, R.; Prasad, V.; Mevis, F.M.; Bhatt, P.; Arunkumar, G. Currently circulating genotypes of Hepatitis A virus in South West, East and North East India, 2017-2018. Med. J. Armed. Forces. India. 2022, 78, 185–191. [Google Scholar] [CrossRef] [PubMed]
- Widell, A.; Hansson, B.G.; Öberg, B.; Nordenfelt, E. Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus. Antivir. Res. 1986, 6, 103–112. [Google Scholar] [CrossRef] [PubMed]
- Crance, J.M.; Biziagos, E.; Passagot, J.; van Cuyck-Gandré, H.; Deloince, R. Inhibition of hepatitis A virus replication in vitro by antiviral compounds. J. Med. Virol. 1990, 31, 155–160. [Google Scholar] [CrossRef] [PubMed]
- Debing, Y.; Kaplan, G.G.; Neyts, J.; Jochmans, D. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication. Antivir. Res. 2013, 98, 325–331. [Google Scholar] [CrossRef] [PubMed]
- Sasaki-Tanaka, R.; Nagulapalli Venkata, K.C.; Okamoto, H.; Moriyama, M.; Kanda, T. Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking. Int. J. Mol. Sci. 2022, 23, 6044. [Google Scholar] [CrossRef] [PubMed]
- Trias, E.; Ibarburu, S.; Barreto-Núñez, R.; Babdor, J.; Maciel, T.T.; Guillo, M.; Gros, L.; Dubreuil, P.; Díaz-Amarilla, P.; Cassina, P.; et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflamm. 2016, 13, 177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trias, E.; Ibarburu, S.; Barreto-Núñez, R.; Varela, V.; Moura, I.C.; Dubreuil, P.; Hermine, O.; Beckman, J.S.; Barbeito, L. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight 2017, 2, e95934. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trias, E.; King, P.H.; Si, Y.; Kwon, Y.; Varela, V.; Ibarburu, S.; Kovacs, M.; Moura, I.C.; Beckman, J.S.; Hermine, O.; et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight 2018, 3, e123249. [Google Scholar] [CrossRef] [PubMed]
- Pogliaghi, M.; Papagno, L.; Lambert, S.; Calin, R.; Calvez, V.; Katlama, C.; Autran, B. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients. AIDS 2014, 28, 278–281. [Google Scholar] [CrossRef] [PubMed]
- Bermejo, M.; López-Huertas, M.R.; García-Pérez, J.; Climent, N.; Descours, B.; Ambrosioni, J.; Mateos, E.; Rodríguez-Mora, S.; Rus-Bercial, L.; Benkirane, M.; et al. Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochem. Pharmacol. 2016, 106, 30–45. [Google Scholar] [CrossRef] [PubMed]
- Bürckstümmer, T.; Kriegs, M.; Lupberger, J.; Pauli, E.K.; Schmittel, S.; Hildt, E. Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett. 2006, 580, 575–580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Himmelsbach, K.; Sauter, D.; Baumert, T.F.; Ludwig, L.; Blum, H.E.; Hildt, E. New aspects of an anti-tumour drug: Sorafenib efficiently inhibits HCV replication. Gut 2009, 58, 1644–1653. [Google Scholar] [CrossRef] [PubMed]
- Descamps, V.; Helle, F.; Louandre, C.; Martin, E.; Brochot, E.; Izquierdo, L.; Fournier, C.; Hoffmann, T.W.; Castelain, S.; Duverlie, G.; et al. The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. Antivir. Res. 2015, 118, 93–102. [Google Scholar] [CrossRef] [PubMed]
- Tsai, B.P.; Jimenez, J.; Lim, S.; Fitzgerald, K.D.; Zhang, M.; Chuah, C.T.H.; Axelrod, H.; Nelson, L.; Ong, S.T.; Semler, B.L.; et al. A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1. Open Biol. 2014, 4, 140180. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, X.; Kanda, T.; Wu, S.; Nakamoto, S.; Saito, K.; Shirasawa, H.; Kiyohara, T.; Ishii, K.; Wakita, T.; Okamoto, H.; et al. Suppression of La antigen exerts potential antiviral effects against hepatitis A virus. PLoS ONE 2014, 9, e101993. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Klopfleisch, R.; Meyer, A.; Schlieben, P.; Bondzio, A.; Weise, C.; Lenze, D.; Hummel, M.; Einspanier, R.; Gruber, A.D. Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes. BMC Vet. Res. 2012, 8, 96. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Semba, Y.; Yamamoto, S.; Takahashi, S.; Shinomiya, T.; Nagahara, Y. c-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells. Eur. J. Pharmacol. 2022, 931, 175183. [Google Scholar] [CrossRef] [PubMed]
- Marech, I.; Ammendola, M.; Leporini, C.; Patruno, R.; Luposella, M.; Zizzo, N.; Passantino, G.; Sacco, R.; Farooqi, A.A.; Zuccalà, V.; et al. C-Kit receptor and tryptase expressing mast cells correlate with angiogenesis in breast cancer patients. Oncotarget 2017, 9, 7918–7927. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marech, I.; Gadaleta, C.D.; Ranieri, G. Possible prognostic and therapeutic significance of c-Kit expression, mast cell count and microvessel density in renal cell carcinoma. Int. J. Mol. Sci. 2014, 15, 13060–13076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martínez-Ortega, U.; Figueroa-Figueroa, D.I.; Hernández-Luis, F.; Aguayo-Ortiz, R. In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease. ChemMedChem 2021, 16, 2339–2344. [Google Scholar] [CrossRef] [PubMed]
- Drayman, N.; DeMarco, J.K.; Jones, K.A.; Azizi, S.A.; Froggatt, H.M.; Tan, K.; Maltseva, N.I.; Chen, S.; Nicolaescu, V.; Dvorkin, S.; et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science 2021, 373, 931–936. [Google Scholar] [CrossRef] [PubMed]
- Bakacs, T.; Sandig, V.; Kovesdi, I. An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination. Cureus 2022, 14, e28467. [Google Scholar] [CrossRef] [PubMed]
- Bakacs, T.; Chumakov, K.; Safadi, R.; Kovesdi, I. Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections. Front. Immunol. 2022, 13, 1046851. [Google Scholar] [CrossRef] [PubMed]
- Kanda, T.; Nakamoto, S.; Wu, S.; Nakamura, M.; Jiang, X.; Haga, Y.; Sasaki, R.; Yokosuka, O. Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus. J. Clin. Transl. Hepatol. 2015, 3, 205–210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosa, S.G.V.; Santos, W.C. Clinical trials on drug repositioning for COVID-19 treatment. Rev. Panam. Salud. Publica 2020, 44, e40. [Google Scholar] [CrossRef] [PubMed]
- Kanda, T.; Sasaki, R.; Masuzaki, R.; Matsumoto, N.; Ogawa, M.; Moriyama, M. Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection. Viruses 2020, 12, 533. [Google Scholar] [CrossRef] [PubMed]
- Woodard, L.E.; Wilson, M.H. piggyBac-ing models and new therapeutic strategies. Trends Biotechnol. 2015, 33, 525–533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Targets | Directions | Sequences of Primers |
---|---|---|
For making inserts HAV/Luc of PiggyBac Transposon | ||
pT7-18f-LUC | Sense | 5′-TAGAGCTAGCGAATTTAATACGACTCACTATAGGG-3′ |
pT7-18f-LUC | Antisense | 5′-ATTTAAATTCGAATTGTCAGGTGGCACTTTTCG-3′ |
For real-time RT-PCR | ||
HAV | Sense | 5′-AGGCTACGGGTGAAACCTCTTAG-3′ |
HAV | Antisense | 5′-GCCGCTGTTACCCTATCCAA-3′ |
Actin | Sense | 5′-CAGCCATGTACGTTGCTATCCAGG-3′ |
Actin | Antisense | 5′-AGGTCCAGACGCAGGATGGCATG-3′ |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sasaki-Tanaka, R.; Shibata, T.; Moriyama, M.; Kogure, H.; Hirai-Yuki, A.; Okamoto, H.; Kanda, T. Masitinib Inhibits Hepatitis A Virus Replication. Int. J. Mol. Sci. 2023, 24, 9708. https://doi.org/10.3390/ijms24119708
Sasaki-Tanaka R, Shibata T, Moriyama M, Kogure H, Hirai-Yuki A, Okamoto H, Kanda T. Masitinib Inhibits Hepatitis A Virus Replication. International Journal of Molecular Sciences. 2023; 24(11):9708. https://doi.org/10.3390/ijms24119708
Chicago/Turabian StyleSasaki-Tanaka, Reina, Toshikatsu Shibata, Mitsuhiko Moriyama, Hirofumi Kogure, Asuka Hirai-Yuki, Hiroaki Okamoto, and Tatsuo Kanda. 2023. "Masitinib Inhibits Hepatitis A Virus Replication" International Journal of Molecular Sciences 24, no. 11: 9708. https://doi.org/10.3390/ijms24119708